The Effect of Titanium-Prepared Platelet-Rich Fibrin (T-PRF) Treatment on the Angiogenic Biomarkers in Gingival Crevicular Fluid (GCF) in Infrabony Defects of Patients With Chronic Periodontitis: A Randomized Controlled Clinical Trial
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Chronic Periodontitis
- Sponsor
- Kırıkkale University
- Enrollment
- 25
- Primary Endpoint
- Platelet-derived growth factor-BB (ng/µl) , vascular endothelial growth factor-A (ng/µl), fibroblast growth factor-2 (ng/µl), anjiogenin (ng/µl), angiostatin (ng/µl)
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This study investigates the effect of titanium-prepared platelet-rich fibrin (T-PRF) treatment on the angiogenic biomarkers in gingival crevicular fluid (GCF) in infrabony defects of patients with chronic periodontitis. In each patient, the infrabony defect of one side of arch was designated as control group (allograft), while the infrabony defect on the contralateral side of same arch was designated as test group (allograft+T-PRF).
Detailed Description
Platelets are the cells initiating the wound healing and also supporting it by secreting various growth factors actively. These growth factors released by platelets act the increase of connective tissue healing, bone regeneration and repair, fibroblast mitogenesis, wound angiogenesis and the activation of macrophages by stimulating cell proliferation signals. Titanium-prepared, platelet-rich fibrin (T-PRF), is a new platelet concentrate, is formed in titanium tubes may be more efficient to activate platelets in comparison with glass tubes.The titanium tubes is utilized to refrain any inverse effects of glass tubes and also silica.
Investigators
Meltem Karsiyaka Hendek
Corresponding author, Clinical Research
Kırıkkale University
Eligibility Criteria
Inclusion Criteria
- •Clinical Diagnosis of Chronic Periodontitis
- •The presence of two or three-wall intrabony defects≥3 mm deep along with an interproximal probing depth ≥5 mm after non-surgical periodontal therapy
Exclusion Criteria
- •Systemic illnesses
- •Any medications known to affect the outcomes of periodontal surgery
- •Pregnancy and lactation
Outcomes
Primary Outcomes
Platelet-derived growth factor-BB (ng/µl) , vascular endothelial growth factor-A (ng/µl), fibroblast growth factor-2 (ng/µl), anjiogenin (ng/µl), angiostatin (ng/µl)
Time Frame: Within the first 30 days after surgery
Secondary Outcomes
- The Volume of Gingival Crevicular Fluid (microliter)(Within the first 30 days after surgery)